{{Short description|Category of drugs used to classify a drug according to certain criteria}}
...on]] (i.e. binding to the same [[biological target]]), a related [[mode of action]], and/or are used to treat the same disease.
...
7 KB (907 words) - 10:49, 25 March 2024
{{Short description|Category of drugs used to classify a drug according to certain criteria}}
...on]] (i.e. binding to the same [[biological target]]), a related [[mode of action]], and/or are used to treat the same disease.
...
7 KB (941 words) - 10:47, 25 March 2024
...iological target/ja|生物学的標的]]に結合する）を持ち、関連した[[mode of action/ja|作用機序(mode of action)]]を持ち、および/または同じ疾患の治療に用いられる[[medication/ja|医薬品]]およびその他の化合物の集合である。
薬物クラス一覧: [https://www.drugs.com/drug-classes.html]
...
9 KB (422 words) - 17:29, 25 March 2024
| ImageName = Skeletal formula of biguanide
| ImageName1 = Ball and stick model of biguanide
...
6 KB (835 words) - 19:05, 23 April 2024
| ImageName = Skeletal formula of biguanide
| ImageName1 = Ball and stick model of biguanide
...
7 KB (877 words) - 19:03, 23 April 2024
| Drugs.com = {{drugs.com|monograph|omega-3-acid-ethyl-esters}}
| routes_of_administration = [[By mouth/ja]]
...
13 KB (590 words) - 22:14, 15 April 2024
...recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.
...-based]] guideline most recently updated in 2018 by the [[American College of Cardiology]] & [[American Heart Association]].
...
6 KB (772 words) - 10:25, 16 April 2024
...recommends the descriptor 'lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'.
...-based]] guideline most recently updated in 2018 by the [[American College of Cardiology]] & [[American Heart Association]].
...
6 KB (794 words) - 10:24, 16 April 2024
| Drugs.com = {{drugs.com|monograph|glimepiride}}
| routes_of_administration = [[Oral administration|By mouth]]
...
7 KB (812 words) - 22:54, 13 March 2024
| Drugs.com = {{drugs.com|monograph|glimepiride}}
| routes_of_administration = [[Oral administration|By mouth]]
...
7 KB (848 words) - 22:53, 13 March 2024
{{Short description|Agonist of the GLP-1 receptor used in the treatment of type 2 diabetes}}
...actions of the endogenous [[incretin]] hormone [[GLP-1]] that is released by the gut after eating.
...
13 KB (1,847 words) - 16:47, 13 April 2024
{{Short description|Class of organic compounds used in medicine and agriculture}}
...eneral structural formula of a sulfonylurea. The functional group consists of a sulfonyl group and a N-substituted ureylene group]]
...
12 KB (1,572 words) - 20:36, 12 March 2024
{{Short description|Agonist of the GLP-1 receptor used in the treatment of type 2 diabetes}}
...actions of the endogenous [[incretin]] hormone [[GLP-1]] that is released by the gut after eating.
...
14 KB (1,899 words) - 16:46, 13 April 2024
| Drugs.com = {{drugs.com|monograph|telmisartan}}
| routes_of_administration = [[Oral administration|By mouth]]
...
8 KB (1,021 words) - 16:03, 28 March 2024
{{Short description|Class of organic compounds used in medicine and agriculture}}
...eneral structural formula of a sulfonylurea. The functional group consists of a sulfonyl group and a N-substituted ureylene group]]
...
12 KB (1,638 words) - 20:35, 12 March 2024
| Drugs.com = {{drugs.com|monograph|sitagliptin}}
| routes_of_administration = [[Oral administration|By mouth]]
...
8 KB (1,202 words) - 20:17, 12 March 2024
| Drugs.com = {{drugs.com|monograph|telmisartan}}
| routes_of_administration = [[Oral administration|By mouth]]
...
8 KB (1,075 words) - 16:02, 28 March 2024
| caption = Chemical structure of [[ethyl eicosapentaenoate]], an important omega-3-acid ethyl ester
| Drugs.com = {{drugs.com|monograph|omega-3-acid-ethyl-esters}}
...
11 KB (1,574 words) - 22:14, 15 April 2024
| Drugs.com = {{drugs.com|monograph|sitagliptin}}
| routes_of_administration = [[Oral administration|By mouth]]
...
9 KB (1,250 words) - 20:17, 12 March 2024
| Drugs.com = {{drugs.com|monograph|insulin_glargine}}
...] form of [[insulin (medication)|medical insulin]], used in the management of [[type 1 DM|type I]] and [[type II diabetes]]. It is [[subcutaneous injecti
...
9 KB (1,241 words) - 11:01, 20 March 2024